Johns Hopkins Researchers Target a New Immune Cell to Potentially Reverse Type 1 Diabetes

Type 1 diabetes develops when the body's own immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. For decades, researchers have sought ways to stop this autoimmune attack and preserve or restore the body's ability to make insulin. Now, Johns Hopkins researchers and their collaborators are pursuing a promising new direction based on a discovery made seven years ago.

The team identified an immune cell they call the X cell, which appears to play a key role in the development of Type 1 diabetes. Rather than simply managing blood sugar after the disease has taken hold, the researchers are exploring how understanding this cell could lead to a therapy that addresses the root cause: the immune system's attack on beta cells.

Building on their discovery, the Johns Hopkins team developed an antibody designed to target the X cell and stop the autoimmune response. According to findings published in the Journal of Immunology in April 2026, this antibody was able to target and eliminate immune cells involved in attacking beta cells in preclinical models—laboratory and animal studies conducted before human testing.

The therapy follows natural patterns observed in both humans and mice, using what researchers describe as a natural antibody to selectively protect insulin-producing cells from destruction. "It's not just managing blood sugar, but potentially correcting the immune dysfunction caused by the disease," explains Rafid Al-Hallaf, a research fellow in the laboratory. "This discovery opens a new direction for thinking about treatment."

While the early results are encouraging, it is important to understand where this research stands. The antibody has been tested only in preclinical models, meaning it has not yet been studied in human patients. Abdel-Rahim A. Hamad, the principal investigator leading the work, emphasizes that "these are novel concepts," signaling that the field is still in the exploratory phase.

The research represents years of federally supported discovery and opens a new avenue for thinking about Type 1 diabetes treatment—one that could potentially intervene shortly after diagnosis to preserve beta cell function. However, additional research and clinical trials will be needed before any new therapy could become available to patients.

Origin: eurekalert.org (News report). Evidence: News report, corroborated with 5 indexed studies. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.